Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

(2014) L. Lopez-Corral et al.   HAEMATOLOGICA

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

New directions in ER stress-induced cell death

(2013) Susan E. Logue et al.   APOPTOSIS

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

HDAC4 protects cells from ER stress induced apoptosis through interaction with ATF4

(2013) Pengfei Zhang et al.   CELLULAR SIGNALLING

New Strategies in the Treatment of Multiple Myeloma

(2013) N. C. Munshi et al.   CLINICAL CANCER RESEARCH

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

(2013) D Cirstea et al.   LEUKEMIA

HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress

(2013) Nirmalya Sen et al.   MOLECULAR CELL

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

(2013) Mercedes Lobera et al.   Nature Chemical Biology

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Blockade of XBP1 splicing by inhibition of IRE1  is a promising therapeutic option in multiple myeloma

(2012) N. Mimura et al.   BLOOD

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

(2011) S. J. Harrison et al.   BLOOD

Peroxisome proliferator-activated receptor γ is inhibited by histone deacetylase 4 in cortical neurons under oxidative stress

(2011) Yang Yang et al.   JOURNAL OF NEUROCHEMISTRY

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress

(2011) Ira Tabas et al.   NATURE CELL BIOLOGY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

(2010) Daniel Antunes Moreno et al.   BRITISH JOURNAL OF HAEMATOLOGY

HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth

(2010) T. Milde et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase 9 (HDAC9) Regulates the Functions of the ATDC (TRIM29) Protein

(2010) Zhigang Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Biologic sequelae of I B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

(2009) T. Hideshima et al.   BLOOD

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY